Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms
Jazyk angličtina Země Japonsko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- bcr-abl fúzní proteiny genetika MeSH
- chinazoliny terapeutické užití MeSH
- dospělí MeSH
- inhibitory agregace trombocytů terapeutické užití MeSH
- Janus kinasa 2 genetika MeSH
- lidé středního věku MeSH
- lidé MeSH
- mutace MeSH
- myeloproliferativní poruchy komplikace diagnóza genetika MeSH
- rizikové faktory MeSH
- senioři MeSH
- střední objem trombocytu * MeSH
- studie případů a kontrol MeSH
- trombocyty * metabolismus patologie MeSH
- trombóza krev farmakoterapie etiologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- anagrelide MeSH Prohlížeč
- bcr-abl fúzní proteiny MeSH
- chinazoliny MeSH
- inhibitory agregace trombocytů MeSH
- Janus kinasa 2 MeSH
BCR/ABL-negative myeloproliferative neoplasms (MPNs) are considered to be acquired thrombophilic conditions. Persistently enhanced platelet activation has been described in polycythaemia vera and essential thrombocythaemia (ET), and shown to contribute to a higher risk of arterial and venous thrombotic complications. Recent studies have shown that mean platelet volume (MPV) and immature platelet fraction (IPF) can serve as useful markers of platelet activation and increased risk of thrombosis. The aim of the present study was to investigate the relationship between these parameters and thrombotic events in BCR/ABL-negative MPN. MPV values in patients with BCR/ABL-negative MPN were significantly higher than MPV values of healthy individuals (P < 0.001). No significant difference in MPV or IPF was observed between groups of patients with and without thrombotic complications (P = 0.441; P = 0.110); the difference in IPF values was close to the significance level for patients with ET (P = 0.073). Higher values of IPF were more frequently detected in patients with JAK2 V617F positivity (P = 0.030). These patients had higher MPV more frequently than others, and this difference was close to the significance level (P = 0.056). Further studies should validate the use of platelet parameters to identify patients at high risk.
Zobrazit více v PubMed
Hematology Am Soc Hematol Educ Program. 2005;:409-15 PubMed
Thromb Res. 2002 May 15;106(4-5):171-7 PubMed
Br J Haematol. 2005 Feb;128(3):275-90 PubMed
Blood. 2013 Nov 28;122(23):3787-97 PubMed
Blood. 1992 Oct 15;80(8):1965-71 PubMed
Br J Haematol. 2000 Jul;110(1):116-24 PubMed
Br J Haematol. 2004 Jul;126(1):93-9 PubMed
Eur Heart J. 2001 Sep;22(17):1561-71 PubMed
J Clin Oncol. 2005 Apr 1;23(10):2224-32 PubMed
Platelets. 2012;23(5):336-43 PubMed
Br J Haematol. 2002 May;117(2):399-404 PubMed
Stroke. 2004 Mar;35(3):622-6 PubMed
Br J Haematol. 1969 Sep;17(3):225-9 PubMed
Blood. 2000 Dec 15;96(13):4261-6 PubMed
Arterioscler Thromb Vasc Biol. 2011 May;31(5):1215-8 PubMed
Semin Thromb Hemost. 2006 Apr;32(3):174-207 PubMed
Blood. 1984 Jun;63(6):1372-5 PubMed
Leuk Res. 2009 Jan;33(1):67-73 PubMed
JACC Cardiovasc Interv. 2010 Aug;3(8):828-35 PubMed
Am J Clin Pathol. 1981 Sep;76(3):289-93 PubMed
Int J Lab Hematol. 2009 Apr;31(2):199-206 PubMed
Haematologica. 2004 Feb;89(2):215-32 PubMed
Atherosclerosis. 2010 Dec;213(2):586-91 PubMed
Blood Rev. 2001 Sep;15(3):121-31 PubMed
N Engl J Med. 2005 Jul 7;353(1):33-45 PubMed
Thromb Haemost. 2013 May;109(5):846-53 PubMed
Thromb Haemost. 2008 May;99(5):930-5 PubMed
Thromb Haemost. 2009 Jan;101(1):151-6 PubMed
Am J Med. 2004 Nov 15;117(10):755-61 PubMed
J Thromb Haemost. 2010 Jan;8(1):157-62 PubMed
Blood Cells. 1989;15(1):108-21 PubMed
Am J Hematol. 2009 Feb;84(2):102-8 PubMed
Haematologica. 2006 Feb;91(2):169-75 PubMed
Blood Coagul Fibrinolysis. 1996 Mar;7(2):157-61 PubMed
J Thromb Haemost. 2010 Jan;8(1):148-56 PubMed
Exp Hematol. 2005 May;33(5):523-30 PubMed
Blood. 2011 Sep 1;118(9):2599-601 PubMed
Hematology Am Soc Hematol Educ Program. 2012;2012:571-81 PubMed
